Biogen International GMBH et al v. Mylan Pharmaceuticals Inc.
| Biogen International GMBH and Biogen MA, Inc. |
| Mylan Pharmaceuticals Inc. |
| 1:2017cv00116 |
| June 30, 2017 |
| US District Court for the Northern District of West Virginia |
| Clarksburg Office |
| Monongalia |
| Irene M. Keeley |
| Patent - Abbreviated New Drug Application |
| 35 U.S.C. ยง 271 |
| None |
Follow case documents by RSS
Available Case Documents
The following documents for this case are available for you to view or download:
| Document Text |
|---|
Filing
400
MEMORANDUM OPINION AND ORDER MAKING FINDINGS OF FACT AND GRANTING JUDGMENT IN FAVOR OF THE DEFENDANT, MYLAN PHARMACEUTICALS INC. The Court FINDS that Mylan has satisfied its burden of demonstrating, by clear and convincing evidence, that the asserted claims of the '514 Patent are invalid for lack of written description under § 112. Signed by Senior Judge Irene M. Keeley on 6/18/2020. (wrr)
|
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
